-
Why Making Dramatic Moves: OncoGenex Pharmaceuticals (NASDAQ:OGXI), ImmunoCellular Therapeutics, (NYSEMKT:IMUC), Progenics Pharmaceuticals (NASDAQ:PGNX), Keurig Green Mountain (NASDAQ:GMCR), Eastman Chemical (NYSE:EMN)
On Friday shares of OncoGenex Pharmaceuticals, Inc. (NASDAQ:OGXI) closed at $1.90. Company’s sales growth for last 5 years was 1.20%. OncoGenex Pharmaceuticals, Inc. (NASDAQ:OGXI) announced that it will report its first quarter 2015 financial results on Thursday, May 14, 2015. ImmunoCellular Therapeutics, Ltd. (NYSEMKT:IMUC) in last trading activity advanced 1.09% to close at $0.46. Company…
-
Trader’s Recap: Progenics Pharmaceuticals (NASDAQ:PGNX), PharmAthene (NYSEMKT:PIP), Ducommun Inc. (NYSE:DCO), Agilysys Inc. (NASDAQ:AGYS), Mindray Medical International Limited (NYSE:MR)
On Wednesday shares of Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) closed at $5.53. Company’s sales growth for last 5 years was -1.90% and EPS growth for next 5 years is recorded as 25.00%. Progenics Pharmaceuticals Inc. (NASDAQ:PGNX) on Wednesday reported a loss of $10.3 million in its first quarter. The Tarrytown, New York-based company said it had…
-
Why Making Dramatic Moves: Vical Incorporated (NASDAQ:VICL), Progenics Pharmaceuticals (NASDAQ:PGNX), Twitter Inc (NYSE:TWTR), Oracle Corporation (NYSE:ORCL), Guaranty Bancorp (NASDAQ:GBNK)
On Friday shares of Vical Incorporated (NASDAQ:VICL) closed at $0.92. Company’s sales growth for last 5 years was 3.70%. Vical Incorporated (NASDAQ:VICL) recently announced that it has joined the IPPOX Foundation in a contract to create HIV-antigen plasmid DNA for vaccines that will be part of clinical trials as part of a joint public and…
-
Hot Alert: Progenics Pharmaceuticals (NASDAQ:PGNX), Oracle Corporation (NYSE:ORCL), Universal Health Services Inc. (NYSE:UHS), Lattice Semiconductor Corporation (NASDAQ:LSCC), Marrone Bio Innovations (NASDAQ:MBII)
On Thursday shares of Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) closed at $4.95. Company’s sales growth for last 5 years was -1.90% and EPS growth for next 5 years is recorded as 25.00%. On 24 April, Valeant Pharma (NYSE: VRX) and Progenics Pharmaceuticals, Inc. (Nasdaq: PGNX) announced that the Committee for Medicinal Products for Human Use (CHMP)…
-
Trader’s Watch List: Progenics Pharmaceuticals (NASDAQ:PGNX), SunEdison (NYSE:SUNE), Kinder Morgan (NYSE:KMI), CorEnergy Infrastructure Trust, (NYSE:CORR), Howard Bancorp Inc. (NASDAQ:HBMD)
On Tuesday shares of Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) closed at $5.38. Company’s sales growth for last 5 years was -1.90% and EPS growth for next 5 years is recorded as 25.00%. On April 24, Valeant Pharmaceuticals International, Inc. (NYSE:VRX) and Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) announced that the Committee for Medicinal Products for Human Use (CHMP)…
-
Trader’s Watch List: Twitter (NYSE:TWTR), Progenics Pharmaceuticals (NASDAQ:PGNX), The Container Store Group (NYSE:TCS), WebMD Health Corp. (NASDAQ:WBMD), PBF Energy Inc. (NYSE:PBF)
On Monday shares of Twitter Inc (NYSE:TWTR) closed at $51.66. Company’s EPS growth for next 5 years is recorded as 70.48%. Twitter Inc (NYSE:TWTR)’s chief executive, Dick Costolo, has begun to follow through on his promise to reboot the company after the executive turmoil and product paralysis that dominated 2014. Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) in…
-
Eye Catching Stocks: Progenics Pharmaceuticals (NASDAQ:PGNX), DTS Inc. (NASDAQ:DTSI), Affymetrix Inc. (NASDAQ:AFFX), Energy Transfer Partners, L.P. (NYSE:ETP)
Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) in last trading activity increased 1.53% to close at $5.97. Company weekly performance is 2.40% while its quarterly performance stands at -16.85%. Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) is -23.85% away from its 52 week high. On April 8, Progenics Pharmaceuticals, Inc., (NASDAQ:PGNX), announced that Mark R. Baker, CEO, is scheduled to present…
-
Stocks to Keep Eyes On: Progenics Pharmaceuticals (NASDAQ:PGNX), Sanchez Production Partners (NYSEMKT:SPP), Johnson & Johnson (NYSE:JNJ), PDII, Air Products & Chemicals (NYSE:APD)
Equities researchers at Brean Capital set a $11.00 price target on shares of Progenics Pharmaceuticals Inc (NASDAQ:PGNX) stock in a research report issued on Friday. The firm currently has a a “buy” rating on the stock. Brean Capital’s target price indicates a potential upside of 68.97% from the stock’s previous close. On Wednesday shares of…
-
Stocks Getting Investors Attention: Progenics Pharmaceuticals (NASDAQ:PGNX), LRR Energy, L.P. (NYSE:LRE), Higher One Holdings, (NYSE:ONE), Vaalco Energy (NYSE:EGY), Liberty Global (NASDAQ:LBTYA)
Progenics Pharmaceuticals, Inc., (NASDAQ:PGNX) announced that long-term follow-up data from its ongoing pivotal Phase 2 Study of AzedraTM in patients with pheochromocytoma and paraganglioma will be presented at the Endocrine Society’s 97th Annual Meeting, taking place from March 5-8, 2015 in San Diego, California. On Thursday shares of Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) closed at $6.82.…